Poxel to Present Imeglimin Data at the American Diabetes Association’s 76th Scientific Sessions

Download as PDF

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that two abstracts have been accepted for poster presentations, which include a moderated poster discussion session, at the American Diabetes Association’s 76th Scientific Sessions, held June 10 – 14 in New Orleans, Louisiana.

Poster Information

Abstract #1197-P
Title: “Imeglimin Improves Insulin Sensitivity in an Adult STZ Rat Model”
Session Name: 12-E Clinical Therapeutics/New Technology–Oral Agents
Date, Time & Location: Sunday, June 12, 2016, 12:00 PM - 2:00 PM, the Poster Hall

Abstract #1081-P
Title: “Imeglimin Increases Insulin Secretion in Response to Glucose as a Unique Mechanism of Action Depending on NAD Synthesis”
Session Name: 12-E Clinical Therapeutics/New Technology–Oral Agents
Date, Time & Location: Sunday, June 12, 2016, 12:00 PM - 2:00 PM, the Poster Hall. In addition, this poster has also been selected to be showcased in the moderated poster discussion session “The Oral Agent Pipeline – Which Will Be the Next New Class of Therapies?” on Monday, June 13, 2016 1:00 PM - 2:00 PM.

Poxel will announce the results through a press release right after the data presentations.

About Imeglimin
Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas. Imeglimin’s unique mechanism of action targets the mitochondrial bioenergetics. This distinct mode of action compared to existing treatments for type 2 diabetes makes Imeglimin a prime candidate in monotherapy and to complement other treatments such as metformin or sitagliptin.

About Poxel
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have entered Phase 2b clinical development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, which is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Poxel SA
Jonae R. Barnes, +1-617-818-2985
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer, + 49 89 2424 3494
or
Stephanie May, + 49 175 571 1562
smay@macbiocom.com
or
Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr

Source: Poxel SA

Released May 17, 2016